AGEN
Agenus Inc

12,484
Mkt Cap
$127.53M
Volume
291,863.00
52W High
$7.34
52W Low
$1.38
PE Ratio
-1.76
AGEN Fundamentals
Price
$3.92
Prev Close
$3.75
Open
$3.85
50D MA
$3.89
Beta
1.91
Avg. Volume
633,510.55
EPS (Annual)
-$10.59
P/B
-0.45
Rev/Employee
$327,414.56
Loading...
Loading...
News
all
press releases
Agenus (AGEN) Q3 2024 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·4d ago
News Placeholder
More News
News Placeholder
Agenus (AGEN) Q1 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·4d ago
News Placeholder
Agenus (AGEN) Q4 2024 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·4d ago
News Placeholder
Short Interest in Agenus Inc. (NASDAQ:AGEN) Rises By 56.5%
Agenus Inc. (NASDAQ:AGEN - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 2,774,043 shares...
MarketBeat·11d ago
News Placeholder
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating...
Business Wire·17d ago
News Placeholder
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages
Shares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have been given an average rating of "Hold" by the five analysts that are currently covering the company, MarketBeat reports. One equities...
MarketBeat·23d ago
News Placeholder
Agenus Inc. (NASDAQ:AGEN) Receives Average Rating of "Hold" from Analysts
Shares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have been given a consensus recommendation of "Hold" by the five brokerages that are presently covering the company, MarketBeat Ratings reports...
MarketBeat·2mo ago
News Placeholder
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session...
Business Wire·2mo ago
News Placeholder
Agenus Appoints Dr. Jos Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including Frances AAC
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of Jos Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias...
Business Wire·2mo ago
News Placeholder
HC Wainwright Has Bullish Outlook for Agenus FY2025 Earnings
Agenus Inc. (NASDAQ:AGEN - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Agenus in a note issued to investors on Tuesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest AGEN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.